Us Psychedelic Mushroom Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The market covers psilocybin mushroom production and derivative products, ranging from whole dried fruiting bodies and cultivated biomass to standardized extracts and pharmaceutical-grade formulations. Valuation encompasses both the illicit underground economy and the fast-growing regulated segments, including licensed clinical trials, therapeutic centers, and jurisdictions that have decriminalized or legalized possession. The United States represents the largest single-country market globally, driven by a patchwork of state-level regulatory changes that have outpaced federal scheduling, which continues to classify psilocybin as a Schedule I substance.

• •U.S. market estimated at approximately $2.25 billion in 2024, reaching roughly $2.799 billion in 2026, with projections extending to over $8 billion by 2035 under higher-growth scenarios
• •Compound annual growth rates across credible forecasts range from 9% to 15.8%, reflecting differing scope definitions and regulatory timeline assumptions
• •Market spans illicit, decriminalized, and regulated commercial segments, with the regulatory-licensed portion still representing a minority of total valuation

The primary catalyst is the accumulating clinical evidence demonstrating psilocybin's efficacy for major depressive disorder, PTSD, substance use disorders, and existential distress in seriously ill patients. FDA breakthrough therapy designation for multiple psilocybin-based candidates has legitimized investment and accelerated the development of standardized manufacturing and delivery protocols. Concurrently, a grassroots decriminalization movement has passed local and state-level reforms in dozens of U.S. jurisdictions, creating an expanding consumer market that operates alongside, and increasingly interacts with, the clinical and research pipeline.

• •FDA breakthrough therapy designations and ongoing Phase III trials are unlocking institutional investment and pharmaceutical-grade manufacturing scale-up
• •Decriminalization and regulated access measures enacted in an expanding number of U.S. cities and states are widening the addressable consumer base
• •Public and private research funding for psychedelic therapeutics has grown substantially, reducing scientific uncertainty and supporting evidence-based product development

Product segmentation includes whole dried mushrooms, mushroom-derived extracts and tinctures, compounded formulations for clinical use, and pharmaceutical-grade psilocybin produced via synthetic or biosynthetic routes. The U.S. dominates North American market value, with regional concentration highest in states that have enacted reform legislation, including Oregon, Colorado, California, and Washington. Canada presents a notable secondary market, with its growing licensed producer ecosystem and Health Canada regulatory exemptions for psychedelic-assisted therapy contributing to regional throughput. Within the United States, informal or gray-market activity remains geographically widespread, but formal commercial activity clusters in reform jurisdictions.

• •U.S. accounts for the overwhelming majority of North American market value, with regional demand strongly correlated to decriminalization and medical access policy adoption
• •Product mix is shifting from informal dried-fruiting-body sales toward standardized extracts, encapsulated formulations, and pharmaceutical-grade active pharmaceutical ingredients
• •Canada's regulated producer framework and exemptions for therapeutic use position it as the second-largest North American market, though materially smaller than the United States

Who are the notable companies in the industry?

I'd like to help, but there's a constraint I need to flag: the research text you provided only contains factual information about **one** of the six companies, **Filament Health**. The other five names (SMC Mushroom Farms, Monterey Mushrooms, Premier Mushrooms, The Mushroom Hub, Magicfly) do not appear anywhere in the provided research, so I have no source material to draw descriptors from for them. Since you've asked me to draw descriptors **only** from the research text, I cannot invent or infer roles for those five companies. What I can do: 1. **Write the section including all six names**, but for the five without research coverage, I'd have to leave their descriptors absent or generic, which would defeat the purpose. 2. **Write the section with just Filament

• •Market is structurally fragmented across both informal and formal segments, with no dominant national-scale producer emerging as a clear market-share leader
• •Production spans a spectrum from small-scale independent cultivators to vertically integrated licensed operators and contract manufacturers serving clinical and pharmaceutical clients
• •Capacity is geographically concentrated in U.S. states with permissive regulatory environments, particularly the Pacific Northwest, Colorado, and California, with Canada's licensed production concentrated in its established regulated cannabis and biotech manufacturing zones

What are the recent trends and outlook?

A central dynamic shaping the near-term trajectory is the federal rescheduling process, which, if psilocybin is moved from Schedule I to a lower schedule, would dramatically expand market scale by enabling insurance reimbursement, mainstream clinical adoption, and large-scale pharmaceutical development. Regardless of federal scheduling pace, state-level regulatory momentum is expected to continue expanding access frameworks. Product standardization, quality certification, and supply chain formalization are emerging as competitive differentiators as the market transitions from informal toward regulated structures. Long-term projections incorporating widespread therapeutic adoption and potential over-the-counter or direct-to-consumer pathways position the sector among the fastest-growing segments of the global mental health and wellness market.

• •Potential federal rescheduling of psilocybin is the single highest-impact near-term catalyst, with implications for reimbursement, clinical scale, and market valuation multiples
• •Product standardization, third-party testing, and supply chain traceability are becoming baseline expectations as regulated commercial channels expand
• •The sector is on a trajectory toward integration with mainstream healthcare delivery, which would fundamentally alter addressable market size and competitive dynamics